Streetbeat News

Revenues

INBX

Inhibrx (NASDAQ:INBX) reported Q4 2023 GAAP EPS of $(1.73), missing the $(1.04) estimate, but sales of $1.63M exceeded the $50.00K estimate, marking a 496.35% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:21 pm

IVDA

Iveda's exclusive distribution partner in Latin America projects FY24 revenue of $6M, with expectations of $30M in recurring revenue over the next five years. This forecast follows a series of efforts and presentations throughout 2023 aimed at establishing Iveda as a leader in AI technology.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:10 pm

ACMR

ACM Research, Inc (NASDAQ:ACMR) reported Q4 fiscal 2023 revenues of $170.3 million, surpassing analyst expectations and marking a 56.9% year-over-year increase. The company's adjusted EPS of $0.43 also beat forecasts, contributing to a significant stock price surge. Despite a decrease in total shipments and a slight decline in adjusted gross margin, ACMR's strong sales in various equipment and services sectors and a positive outlook for FY24, projecting revenues between $650 million and $725 million, have bolstered investor confidence. The company's performance and future prospects are influenced by macroeconomic factors, including interest rates, inflation, and labor market conditions.

Portfolio Pulse from Anusuya Lahiri

February 28, 2024 | 2:07 pm

NVAX

Novavax shares dropped following the announcement of disappointing Q4 sales results and Q1 revenue guidance that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:07 pm

OCUL

VFC

WES

Insiders at V.F. Corporation, Western Midstream Partners, and Ocular Therapeutix have made significant stock purchases, indicating confidence in their companies. V.F. Corporation expanded its board, Western Midstream reported increased revenue, and Ocular Therapeutix announced a $325 million private placement.

Portfolio Pulse from Avi Kapoor

February 28, 2024 | 2:06 pm

CAH

SCLX

Scilex Holding Company announced that its anti-gout medication, GLOPERBA®, will be stocked in leading national pharmacy chains across the U.S. ahead of its expected launch in the first half of 2024. The company is also negotiating with additional chains for stocking arrangements. GLOPERBA®, the first liquid oral colchicine for gout prophylaxis, targets the growing gout treatment market, projected to reach $2.0 billion by 2028. Scilex has increased GLOPERBA® production, with inventory available at Cardinal Health.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:02 pm

CRDO

Credo Technology Group (NASDAQ:CRDO) has received mixed analyst ratings over the past three months, with a recent trend towards more bullish perspectives. The average 12-month price target for CRDO has been raised to $26.2, indicating a 10.32% increase from the previous target. Analysts from Mizuho, Needham, and Goldman Sachs have adjusted their ratings and price targets, reflecting optimism about CRDO's future performance despite challenges in revenue growth and profitability.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 2:00 pm

VRDN

Viridian Therapeutics (NASDAQ:VRDN) has received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for VRDN has been adjusted to $35.83, down from $37.00, reflecting a 3.16% decrease. The company, a clinical-stage biopharmaceutical firm focusing on thyroid eye disease treatments, faces financial challenges, including a significant revenue decline and below-industry benchmarks in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 2:00 pm

CETX

Cemtrex Inc. (NASDAQ:CETX) issued a shareholder letter providing a corporate update, highlighting restructuring efforts, investments, and financial performance. The letter, from CEO Saagar Govil, discusses the company's exit from certain businesses, the promising outlook of its Security and Industrial segments, and significant improvements in financial metrics. The company owns Vicon Industries and Advanced Industrial Services, which have shown strong sales growth and operational improvements. The letter emphasizes Cemtrex's focus on generating higher returns than the S&P 500 and the potential for future growth.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:38 pm

NNDM

Nano Dimension announced the sale of a second 3D printer for electronics to an existing customer, indicating repeat business and potential growth in customer satisfaction and product reliability.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:36 pm